ES2553442T3 - Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón - Google Patents
Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón Download PDFInfo
- Publication number
- ES2553442T3 ES2553442T3 ES12165740.7T ES12165740T ES2553442T3 ES 2553442 T3 ES2553442 T3 ES 2553442T3 ES 12165740 T ES12165740 T ES 12165740T ES 2553442 T3 ES2553442 T3 ES 2553442T3
- Authority
- ES
- Spain
- Prior art keywords
- mir
- lung cancer
- level
- gene products
- micrornas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
Un procedimiento para diagnosticar si un sujeto tiene cáncer de pulmón, que comprende la medición del nivel de los productos génicos de miR en una muestra de ensayo de tejido pulmonar dicho sujeto, en el que una alteración del nivel del producto génico de miR en la muestra de ensayo, con respecto al nivel correspondiente de los productos génicos de miR en una muestra de control, es indicativa de que el sujeto tiene cáncer de pulmón en el que los productos génicos de miR comprenden un grupo de productos génicos de miR, consistiendo dicho grupo en miR- 21, miR-191, miR-155, miR-210, miR-126* y miR-224; y.en el que el nivel de los productos génicos miR-21, miR-191, miR-155 and miR-210 en la muestra de ensayo es mayor que el correspondiente producto génico de miR en la muestra de control y en el que el nivel de los productos génicos miR-126* and miR-224 en la muestra de ensayo es menor que el nivel del correspondiente producto géico de miR en la muestra de control.
Description
documento se llama a un microARN por su nombre, el nombre corresponde tanto a la forma de precursor como a la madura, a menos que se indique otra cosa.
La presente invención engloba un procedimiento para diagnosticar si un sujeto tiene o está en riesgo de desarrollar
5 cáncer de pulmón, comprendiendo la medición de un grupo de productos génicos de miR en una muestra de ensayo del sujeto y comparando el nivel del producto génico de miR en la muestra de ensayo con el nivel del correspondiente producto génico de miR en una muestra de control. Como se utiliza en el presente documento, un “sujeto” puede ser cualquier mamífero que tenga o sea sospechoso de tener un cáncer de pulmón.
10 El cáncer de pulmón puede ser cualquier forma de cáncer de pulmón, por ejemplo, cánceres de pulmón de diferentes histologías (por ejemplo, adenocarcinoma, carcinoma de células escamosas). Además, el cáncer de pulmón se puede asociar con un pronóstico particular (por ejemplo, tasa baja de supervivencia, progresión rápida).
Las Tablas 1a y 1b describen las secuencias de nucleótidos de microARN humanos precursores y maduros. 15 Tabla 1a-Secuencias de precursores de microARN humano
- Nombre del precursor
- Secuencia (5’ a 3’)* SEC ID Nº
- let-7a-1
-
imagen6 1
- let-7a-2
-
imagen7 2
- let-7a-3
-
imagen8 3
- let-7a-4
-
imagen9 4
- let-7b
-
imagen10 5
- let-7c
-
imagen11 6
- let-7d
-
imagen12 7
- let-7d-v1
-
imagen13 8
- let-7d-v2
-
imagen14 9
- let-7e
-
imagen15 10
- let-7f-1
-
imagen16 11
- let-7f-2-1
-
imagen17 12
- let-7f-2-2
-
imagen18 13
- let-7g
-
imagen19 14
- let-7i
-
imagen20 15
- miR-1b-1-1
-
imagen21 16
- miR-1b-1-2
-
imagen22 17
- miR-1b-2
-
imagen23 18
- miR-1b
-
imagen24 19
- miR-1d
-
imagen25 20
- miR-7-1a
-
imagen26 21
- miR-7-1b
-
imagen27 22
- miR-7-2
-
imagen28 23
- miR-7-3
-
imagen29 24
- miR-9-1
-
imagen30 25
- miR-9-2
-
imagen31 26
- miR-9-3
-
imagen32 27
- miR-10a
-
imagen33 28
- miR-10b
-
imagen34 29
- miR-15a-2
-
imagen35 30
- miR-15a
-
imagen36 31
- miR-15b-1
-
imagen37 32
- miR-15b-2
-
imagen38 33
- miR-16-1
-
imagen39 34
- miR-16-2
-
imagen40 35
- miR-16-13
-
imagen41 36
- miR-17
-
imagen42 37
- miR-18
-
imagen43 38
- miR-18-13
-
imagen44 39
- miR-19a
-
imagen45 40
- miR-19a-13
-
imagen46 41
- miR-19b-1
-
imagen47 42
- miR-19b-2
-
imagen48 43
- miR-19b-13
-
imagen49 44
- miR-19b-X
-
imagen50 45
- miR-20 (miR-20a)
-
imagen51 46
- miR-21
-
imagen52 47
- miR-21-17
-
imagen53 48
- miR-22
-
imagen54 49
- miR-23a
-
imagen55 50
- miR-23b
-
imagen56 51
- miR-23-19
-
imagen57 52
- miR-24-1
-
imagen58 53
- miR-24-2
-
imagen59 54
- miR-24-19
-
imagen60 55
- miR-24-9
-
imagen61 56
- miR-25
-
imagen62 57
- miR-26a
-
imagen63 58
- miR-26a-1
-
imagen64 59
- miR-26a-2
-
imagen65 60
- miR-26b
-
imagen66 61
- miR-27a
-
imagen67 62
- miR-27b-1
-
imagen68 63
- miR-27b-2
-
imagen69 64
- miR-27-19
-
imagen70 65
- miR-28
-
imagen71 66
- miR-29a-2
-
imagen72 67
- miR-29a
-
imagen73 68
- miR-29b-1
-
imagen74 69
- miR-29b-2
-
imagen75 70
- miR-29c
-
imagen76 71
- miR-30a
-
imagen77 72
- miR-30b-1
-
imagen78 73
- miR-30b-2
-
imagen79 74
- miR-30c
-
imagen80 75
- miR-30d
-
imagen81 76
- miR-30e
-
imagen82 77
- miR-31
-
imagen83 78
- miR-32
-
imagen84 79
- miR-33b
-
imagen85 80
- miR-33b-2
-
imagen86 81
- miR-33
-
imagen87 82
- miR-34-a
-
imagen88 83
- miR-34-b
-
imagen89 84
- miR-34-c
-
imagen90 85
- miR-91-13
-
imagen91 86
- miR-92-1
-
imagen92 87
- miR-92 -2
-
imagen93 88
- miR-93-1 (miR-93-2)
-
imagen94 89
- miR-95-4
-
imagen95 90
- miR-96-7
-
imagen96 91
- miR-97-6 (miR-30*)
-
imagen97 92
- miR-98
-
imagen98 93
- miR-99b
-
imagen99 94
- miR-99a
-
imagen100 95
- miR-100-1/2
-
imagen101 96
- miR-100-11
-
imagen102 97
- miR-101-1/2
-
imagen103 98
- miR-101
-
imagen104 99
- miR-101-1
-
imagen105 100
- miR-101-2
-
imagen106 101
- miR-101-9
-
imagen107 102
- miR-102-1
-
imagen108 103
- miR-102-7.1 (miR-102-7. 2)
-
imagen109 104
- miR-103-2
-
imagen110 105
- miR-103-1
-
imagen111 106
- miR-104-17
-
imagen112 107
- miR-105-1
-
imagen113 108
- miR-105-2
-
imagen114 109
- miR-106-a
-
imagen115 110
- miR-106-b
-
imagen116 111
- miR-107
-
imagen117 112
- miR-1 08-1-pequeño
-
imagen118 113
- miR-108-2-pequeño
-
imagen119 114
- miR-122a-1
-
imagen120 115
- miR-122a-2
-
imagen121 116
- miR-123
-
imagen122 117
- miR-124a-1
-
imagen123 118
- miR-124a-2
-
imagen124 119
- miR-124a-3
-
imagen125 120
- miR-124a
-
imagen126 121
- miR-124b
-
imagen127 122
- miR-125a-1
-
imagen128 123
- miR-125a-2
-
imagen129 124
- miR-125b-1
-
imagen130 125
- miR-125b-2
-
imagen131 126
- miR-126-1
-
imagen132 127
- miR-126-2
-
imagen133 128
- miR-127-1
-
imagen134 129
- miR-127-2
-
imagen135 130
- miR-128a
-
imagen136 131
- miR-128b
-
imagen137 132
- miR-128
-
imagen138 133
- miR-129-1
-
imagen139 134
- miR-129-2
-
imagen140 135
- miR-130a
-
imagen141 136
- miR-131-1
-
imagen142 137
- miR-131-3
-
imagen143 138
- miR-131
-
imagen144 139
- miR-132-1
-
imagen145 140
- miR-132-2
-
imagen146 141
- miR-133a-1
-
imagen147 142
- miR-133a-2
-
imagen148 143
- miR-133
-
imagen149 144
- miR-133b
-
imagen150 145
- miR-133b-pequeño
-
imagen151 146
- miR-134-1
-
imagen152 147
- miR-134-2
-
imagen153 148
- miR-135a-1
-
imagen154 149
- miR-135a-2 (miR-135-2)
-
imagen155 150
- miR-135
-
imagen156 151
- miR-135b
-
imagen157 152
- miR-136-1
-
imagen158 153
- miR-136-2
-
imagen159 154
- miR-137
-
imagen160 155
- miR-138-1
-
imagen161 156
- miR-138-2
-
imagen162 157
- miR-138
-
imagen163 158
- miR-139
-
imagen164 159
- miR-140
-
imagen165 160
- miR-140as
-
imagen166 161
- miR-140s
-
imagen167 162
- miR-141-1
-
imagen168 163
- miR-141-2
-
imagen169 164
- miR-142
-
imagen170 165
- miR-143-1
-
imagen171 166
- miR-143-2
-
imagen172 167
- miR-144-1
-
imagen173 168
- miR-144-2
-
imagen174 169
- miR-145-1
-
imagen175 170
- miR-145-2
-
imagen176 171
- miR-146-1
-
imagen177 172
- miR-146-2
-
imagen178 173
- miR-147
-
imagen179 174
- miR-148a (miR-148)
-
imagen180 175
- miR-148b
-
imagen181 176
- miR-148b-pequeño
-
imagen182 177
- miR-149-1
-
imagen183 178
- miR-149-2
-
imagen184 179
- miR-150-1
-
imagen185 180
- miR-150-2
-
imagen186 181
- miR-151
-
imagen187 182
- miR-151-2
-
imagen188 183
- miR-152-1
-
imagen189 184
- miR-152-2
-
imagen190 185
- miR-153-1-1
-
imagen191 186
- miR-153-1-2
-
imagen192 187
- miR-153-2-1
-
imagen193 188
- miR-153-2-2
-
imagen194 189
- miR-154-1
-
imagen195 190
- miR-154-2
-
imagen196 191
- miR-155
-
imagen197 192
- miR-156 = miR157=solapamiento miR-141
-
imagen198 193
- miR-158-pequeño = miR-192
-
imagen199 194
- miR-159-1-pequeño
-
imagen200 195
- miR-161-pequeño
-
imagen201 196
- miR-163-1b-pequeño
-
imagen202 197
- miR-163-3-pequeño
-
imagen203 198
- miR-162
-
imagen204 199
- miR-175-pequeño=miR-224
-
imagen205 200
- miR-177-pequeño
-
imagen206 201
- miR-180-pequeño
-
imagen207 202
- miR-181a
-
imagen208 203
- miR-181b-1
-
imagen209 204
- miR-181b-2
-
imagen210 205
- miR-181c
-
imagen211 206
- miR-182-as
-
imagen212 207
- miR-182
-
imagen213 208
- miR-183
-
imagen214 209
- miR-184-1
-
imagen215 210
- miR-184-2
-
imagen216 211
- miR-185-1
-
imagen217 212
- miR-185-2
-
imagen218 213
- miR-186-1
-
imagen219 214
- miR-186-2
-
imagen220 215
- miR-187
-
imagen221 216
- miR-188-1
-
imagen222 217
- miR-188-2
-
imagen223 218
- miR-189-1
-
imagen224 219
- miR-189-2
-
imagen225 220
- miR-190-1
-
imagen226 221
- miR-190-2
-
imagen227 222
- miR-191-1
-
imagen228 223
- miR-191-2
-
imagen229 224
- miR-192-2/3
-
imagen230 225
- miR-192
-
imagen231 226
- miR-193-1
-
imagen232 227
- miR-193-2
-
imagen233 228
- miR-194-1
-
imagen234 229
- miR-194-2
-
imagen235 230
- miR-195-1
-
imagen236 231
- miR-195-2
-
imagen237 232
- miR-196-1
-
imagen238 233
- miR-196a-1
-
imagen239 234
- miR-196a-2 (miR-196-2)
-
imagen240 235
- miR-196
-
imagen241 236
- miR-196b
-
imagen242 237
- miR-197
-
imagen243 238
- miR-197-2
-
imagen244 239
- miR-198
-
imagen245 240
- miR-199a-1
-
imagen246 241
- miR-199a-2
-
imagen247 242
- miR-199b
-
imagen248 243
- miR-199s
-
imagen249 244
- miR-200a
-
imagen250 245
- miR-200b
-
imagen251 246
- miR-200c
-
imagen252 247
- miR-202
-
imagen253 248
- miR-203
-
imagen254 249
- miR-204
-
imagen255 250
- miR-205
-
imagen256 251
- miR-206-1
-
imagen257 252
- miR-206-2
-
imagen258 253
- miR-208
-
imagen259 254
- miR-210
-
imagen260 255
- miR-211
-
imagen261 256
- miR-212
-
imagen262 257
- miR-213-2
-
imagen263 258
- miR-213
-
imagen264 259
- miR-214
-
imagen265 260
- miR-215
-
imagen266 261
- miR-216
-
imagen267 262
- miR-217
-
imagen268 263
- miR-218-1
-
imagen269 264
- miR-218-2
-
imagen270 265
- miR-219
-
imagen271 266
- miR-219-1
-
imagen272 267
- miR-219-2
-
imagen273 268
- miR-220
-
imagen274 269
- miR-221
-
imagen275 270
- miR-222
-
imagen276 271
- miR-223
-
imagen277 272
- miR-224
-
imagen278 273
- Nombre del precursor
- Secuencia (5’ a 3’)* SEC ID Nº
- miR-294-1 (chr16)
-
imagen279 274
- miR-296
-
imagen280 275
- miR-299
-
imagen281 276
- miR-301
-
imagen282 277
- miR-302a
-
imagen283 278
- miR-302b
-
imagen284 279
- miR-302c
-
imagen285 280
- miR-302d
-
imagen286 281
- miR-320
-
imagen287 282
- miR-321
-
imagen288 283
- miR-323
-
imagen289 284
- miR-324
-
imagen290 285
- miR-325
-
imagen291 286
- miR-326
-
imagen292 287
- miR-328
-
imagen293 288
- miR-330
-
imagen294 289
- miR-331
-
imagen295 290
- miR-335
-
imagen296 291
- miR-337
-
imagen297 292
- miR-338
-
imagen298 293
- miR-339
-
imagen299 294
- miR-340
-
imagen300 295
- miR-342
-
imagen301 296
- miR-345
-
imagen302 297
- miR-346
-
imagen303 298
- miR-367
-
imagen304 299
- miR-368
-
imagen305 300
- miR-369
-
imagen306 301
- miR-370
-
imagen307 302
- miR-3 71
-
imagen308 303
- miR-372
-
imagen309 304
- miR-3 73
-
imagen310 305
- miR-374
-
imagen311 306
- miR-hes1
-
imagen312 307
- miR-hes2
-
imagen313 308
- miR-hes3
-
imagen314 309
- * Una secuencia subrayada dentro de una secuencia de precursor corresponde a un transcrito de miR procesado maduro (véase la Tabla 1b). Algunas secuencias de precursor tienen dos secuencias subrayadas que indican dos miR maduros diferentes que se obtienen a partir del mismo precursor. Todas las secuencias son humanas.
Tabla 1b -Secuencias de microRNA Maduro Humano.
- Nombre de miRNA Maduro
- Secuencia de miRNA Maduro (5’ a 3’) SEC ID Nº microRNA precursor correspondiente(s); véase la Tabla 1a
- let-7a
- ugagguaguagguuguauaguu 310 let-7a-1; let-7a-2; let-7a-3; let-7a-4
- let-7b
- ugagguaguagguugugugguu 311
- let-7b
- let-7c
- ugagguaguagguuguaugguu 312
- let-7c
- let-7d
- agagguaguagguugcauagu 313 let-7d; let-7d-v1
- let-7e
- ugagguaggagguuguauagu 314
- let-7e
- let-7f
- ugagguaguagauuguauaguu 315 let-7f-1; let-7f-2-1; let-7f-2-2
- let-7g
- ugagguaguaguuuguacagu 316
- let-7g
- let-7i
- ugagguaguaguuugugcu 317
- let-7i
- miR-1
- uggaauguaaagaaguaugua 318 miR-1b; miR-1b-1; miR-1b-2
- miR-7
- uggaagacuagugauuuuguu 319 miR-7-1; miR-7-1a; miR-7-2; miR-7-3
- miR-9
- ucuuugguuaucuagcuguauga 320 miR-9-1; miR-9-2; miR-9-3
- miR-9*
- uaaagcuagauaaccgaaagu 321 miR-9-1; miR-9-2; miR-9-3
- miR-10a
- uacccuguagauccgaauuugug 322
- miR-10a
- miR-10b
- uacccuguagaaccgaauuugu 323
- miR-10b
- miR-15a
- uagcagcacauaaugguuugug 324 miR-15a; miR-15a-2
- miR-15b
- uagcagcacaucaugguuuaca 325
- miR-15b
- miR-16
- uagcagcacguaaauauuggcg 326 miR-16-1; miR-16-2; miR-16-13
- miR-17-5p
- caaagugcuuacagugcagguagu 327 miR-17
- miR-17-3p
- acugcagugaaggcacuugu 328 miR-17
- miR-18
- uaaggugcaucuagugcagaua 329 miR-18; miR-18-13
- miR-19a
- ugugcaaaucuaugcaaaacuga 330 miR-19a; miR-19a-13
- miR-19b
- ugugcaaauccaugcaaaacuga 331 miR-19b-1; miR-19b-2
- miR-20
- uaaagugcuuauagugcaggua 332 miR-20 (miR-20a)
- miR-21
- uagcuuaucagacugauguuga 333 miR-21; miR-21-17
- miR-22
- aagcugccaguugaagaacugu 334
- miR-22
- miR-23a
- aucacauugccagggauuucc 335
- miR-23a
- miR-23b
- aucacauugccagggauuaccac 336
- miR-23b
- miR-24
- uggcucaguucagcaggaacag 337 miR-24-1; miR-24-2; miR-24-19; miR24-9
- miR-25
- cauugcacuugucucggucuga 338
- miR-25
- miR-26a
- uucaaguaauccaggauaggcu 339 miR-26a; miR-26a-1; miR-26a-2
- miR-26b
- uucaaguaauucaggauaggu 340
- miR-26b
- miR-27a
- uucacaguggcuaaguuccgcc 341
- miR-27a
- miR-27b
- uucacaguggcuaaguucug 342 miR-27b-1; miR-27b-2
- miR-28
- aaggagcucacagucuauugag 343
- miR-28
- miR-29a
- cuagcaccaucugaaaucgguu 344 miR-29a-2; miR-29a
- miR-29b
- uagcaccauuugaaaucagu 345 miR-29b-1; miR-29b-2
- miR-29c
- uagcaccauuugaaaucgguua 346
- miR-29c
- miR-30a-5p
- uguaaacauccucgacuggaagc 347 miR-30a
- miR-30a-3p
- cuuucagucggauguuugcagc 348 miR-30a
- miR-30b
- uguaaacauccuacacucagc 349 miR-30b-1; miR-30b-2
- miR-30c
- uguaaacauccuacacucucagc 350
- miR-30c
- miR-30d
- uguaaacauccccgacuggaag 351
- miR-30d
- miR-30e
- uguaaacauccuugacugga 352
- miR-30e
- miR-31
- ggcaagaugcuggcauagcug 353
- miR-31
- miR-32
- uauugcacauuacuaaguugc 354
- miR-32
- miR-33
- gugcauuguaguugcauug 355 miR-33; miR-33b
- miR-34a
- uggcagugucuuagcugguugu 356
- miR-34a
- miR-34b
- aggcagugucauuagcugauug 357
- miR-34b
- miR-34c
- aggcaguguaguuagcugauug 358
- miR-34c
- miR-92
- uauugcacuugucccggccugu 359 miR-92-2; miR-92-1
- miR-93
- aaagugcuguucgugcagguag 360 miR-93-1; miR-93-2
- miR-95
- uucaacggguauuuauugagca 361
- miR-95
- miR-96
- uuuggcacuagcacauuuuugc 362
- miR-96
- miR-98
- ugagguaguaaguuguauuguu 363
- miR-98
- miR-99a
- aacccguagauccgaucuugug 364
- miR-99a
- miR-99b
- cacccguagaaccgaccuugcg 365
- miR-99b
- miR-100
- uacaguacugugauaacugaag 366
- miR-100
- miR-101
- uacaguacugugauaacugaag 367 miR-101-1; miR-101-2
- miR-103
- agcagcauuguacagggcuauga 368 miR-103-1
- miR-105
- ucaaaugcucagacuccugu 369
- miR-105
- miR-106-a
- aaaagugcuuacagugcagguagc 370
- miR-106-a
- miR-106-b
- uaaagugcugacagugcagau 371
- miR-106-b
- miR-107
- agcagcauuguacagggcuauca 372
- miR-107
- miR-122a
- uggagugugacaaugguguuugu 373 miR-122a-1; miR-122a-2
- miR-124a
- uuaaggcacgcggugaaugcca 374 miR-124a-1; miR-124a-2; miR-124a-3
- miR-125a
- ucccugagacccuuuaaccugug 375 miR-125a-1; miR-125a-2
- miR-125b
- ucccugagacccuaacuuguga 376 miR-125b-1; miR-125b-2
- miR-126*
- cauuauuacuuuugguacgcg 377 miR-126-1; miR-126-2
- miR-126
- ucguaccgugaguaauaaugc 378 miR-126-1; miR-126-2
- miR-127
- ucggauccgucugagcuuggcu 379 miR-127-1; miR-127-2
- miR-128a
- ucacagugaaccggucucuuuu 380 miR-128; miR-128a
- miR-128b
- ucacagugaaccggucucuuuc 381
- miR-128b
- miR-129
- cuuuuugcggucugggcuugc 382 miR-129-1; miR-129-2
- miR-130a
- cagugcaauguuaaaagggc 383
- miR-130a
- miR-130b
- cagugcaaugaugaaagggcau 384
- miR-130b
- miR-132
- uaacagucuacagccauggucg 385 miR-132-1
- miR-133a
- uugguccccuucaaccagcugu 386 miR-133a-1; miR-133a-2
- miR-133b
- uugguccccuucaaccagcua 387
- miR-133b
- miR-134
- ugugacugguugaccagaggg 388 miR-134-1; miR-134-2
- miR-135a
- uauggcuuuuuauuccuauguga 389 miR-135a; miR-135a-2 (miR-135-2)
- miR-135b
- uauggcuuuucauuccuaugug 390
- miR-135b
- miR-136
- acuccauuuguuuugaugaugga 391 miR-136-1; miR-136-2
- miR-137
- uauugcuuaagaauacgcguag 392
- miR-137
- miR-138
- agcugguguugugaauc 393 miR-138-1; miR-138-2
- miR-139
- ucuacagugcacgugucu 394
- miR-139
- miR-140
- agugguuuuacccuaugguag 395 miR-140; miR-140as; miR-140s
- miR-141
- aacacugucugguaaagaugg 396 miR-141-1; miR-141-2
- miR-142-3p
- uguaguguuuccuacuuuaugga 397 miR-142
- miR-142-5p
- cauaaaguagaaagcacuac 398 miR-142
- miR-143
- ugagaugaagcacuguagcuca 399 miR-143-1
- miR-144
- uacaguauagaugauguacuag 400 miR-144-1; miR-144-2
- miR-145
- guccaguuuucccaggaaucccuu 401 miR-145-1; miR-145-2
- miR-146
- ugagaacugaauuccauggguu 402 miR-146-1; miR-146-2
- miR-147
- guguguggaaaugcuucugc 403
- miR-147
- miR-148a
- ucagugcacuacagaacuuugu 404 miR-148a (miR-148)
- miR-148b
- ucagugcaucacagaacuuugu 405
- miR-148b
- miR-149
- ucuggcuccgugucuucacucc 406
- miR-149
- miR-150
- ucucccaacccuuguaccagug 407 miR-150-1; miR-150-2
- miR-151
- acuagacugaagcuccuugagg 408
- miR-151
- miR-152
- ucagugcaugacagaacuugg 409 miR-152-1; miR-152-2
- miR-153
- uugcauagucacaaaaguga 410 miR-153-1-1; miR-153-1-2; miR-1532-1; m iR-153-2-2
- miR-154
- uagguuauccguguugccuucg 411 miR-154-1; miR-154-2
- miR-154*
- aaucauacacgguugaccuauu 412 miR-154-I; miR-154-2
- miR-155
- uuaaugcuaaucgugauagggg 413
- miR-155
- miR-181a
- aacauucaacgcugucggugagu 414
- miR-181a
- miR-181b
- aacauucauugcugucgguggguu 415 miR-181b-1; miR-181b-2
- miR-181c
- aacauucaaccugucggugagu 416
- miR-181c
- miR-182
- uuuggcaaugguagaacucaca 417 miR-182; miR-182as
- miR-182*
- ugguucuagacuugccaacua 418 miR-182; miR-182as
- miR-183
- uauggcacugguagaauucacug 419
- miR-183
- miR-184
- uggacggagaacugauaagggu 420 miR-184-1; miR-184-2
- miR-185
- uggagagaaaggcaguuc 421 miR-185-1; miR-185-2
- miR-186
- caaagaauucuccuuuugggcuu 422 miR-186-1; miR-186-2
- miR-187
- ucgugucuuguguugcagccg 423
- miR-187
- miR-188
- caucccuugcaugguggagggu 424
- miR-188
- miR-189
- gugccuacugagcugauaucagu 425 miR-189-1; miR-189-2
- miR-190
- ugauauguuugauauauuaggu 426 miR-190-1; miR-190-2
- miR-191
- caacggaaucccaaaagcagcu 427 miR-191-1; miR-191-2
- miR-192
- cugaccuaugaauugacagcc 428
- miR-192
- miR-193
- aacuggccuacaaagucccag 429 miR-193-1; miR-193-2
- miR-194
- uguaacagcaacuccaugugga 430 miR-194-1; miR-194-2
- miR-195
- uagcagcacagaaauauuggc 431 miR-195-1; miR-195-2
- miR-196a
- uagguaguuucauguuguugg 432 miR-196a; miR-196a-2 (miR196-2)
- miR-196b
- uagguaguuuccuguuguugg 433
- miR-196b
- miR-197
- uucaccaccuucuccacccagc 434
- miR-197
- miR-198
- gguccagaggggagauagg 435
- miR-198
- miR-199a
- cccaguguucagacuaccuguuc 436 miR-199a-1; miR-199a-2
- miR-199a*
- uacaguagucugcacauugguu 437 miR-199a-1; miR-199a-2; miR-199s; miR-199b
- miR-199b
- cccaguguuuagacuaucuguuc 438
- miR-199b
- miR-200a
- uaacacugucugguaacgaugu 439
- miR-200a
- miR-200b
- cucuaauacugccugguaaugaug 440
- miR-200b
- miR-200c
- aauacugccggguaaugaugga 441
- miR-200c
- miR-202
- agagguauagggcaugggaaga 442
- miR-202
- miR-203
- gugaaauguuuaggaccacuag 443
- miR-203
- miR-204
- uucccuuugucauccuaugccu 444
- miR-204
- miR-205
- uccuucauuccaccggagucug 445
- miR-205
- miR-206
- uggaauguaaggaagugugugg 446 miR-206-1; miR-206-2
- miR-208
- auaagacgagcaaaaagcuugu 447
- miR-208
- miR-210
- cugugcgugugacagcggcug 448
- miR-210
- miR-211
- uucccuuugucauccuucgccu 449
- miR-211
- miR-212
- uaacagucuccagucacggcc 450
- miR-212
- miR-213
- accaucgaccguugauuguacc 451
- miR-213
- miR-214
- acagcaggcacagacaggcag 452
- miR-214
- miR-215
- augaccuaugaauugacagac 453
- miR-215
- miR-216
- uaaucucagcuggcaacugug 454
- miR-216
- miR-217
- uacugcaucaggaacugauuggau 455
- miR-217
- miR-218
- uugugcuugaucuaaccaugu 456 miR-218-1; miR-218-2
- miR-219
- ugauuguccaaacgcaauucu 457 miR-219; miR-219-1; miR-219-2
- miR-220
- ccacaccguaucugacacuuu 458
- miR-220
- miR-221
- agcuacauugucugcuggguuuc 459
- miR-221
- miR-222
- agcuacaucuggcuacugggucuc 460
- miR-222
- miR-223
- ugucaguuugucaaauacccc 461
- miR-223
- miR-224
- caagucacuagugguuccguuua 462
- miR-224
- miR-296
- agggcccccccucaauccugu 463
- miR-296
- miR-299
- ugguuuaccgucccacauacau 464
- miR-299
- miR-301
- cagugcaauaguauugucaaagc 465
- miR-301
- miR-302a
- uaagugcuuccauguuuugguga 466
- miR-302a
- miR-302b*
- acuuuaacauggaagugcuuucu 467 miR-302b
- miR-302b
- uaagugcuuccauguuuuaguag 468
- miR-302b
- miR-302c*
- uuuaacauggggguaccugcug 469 miR-302c
- miR-302c
- uaagugcuuccauguuucagugg 470
- miR-302c
- miR-302d
- uaagugcuuccauguuugagugu 471
- miR-302d
- miR-320
- aaaagcuggguugagagggcgaa 472
- miR-320
- miR-321
- uaagccagggauuguggguuc 473
- miR-321
- miR-323
- gcacauuacacggucgaccucu 474
- miR-323
- miR-324-5p
- cgcauccccuagggcauuggugu 475 miR-324
- miR-324-3p
- ccacugccccaggugcugcugg 476 miR-324
- miR-325
- ccuaguagguguccaguaagu 477
- miR-325
- miR-326
- ccucugggcccuuccuccag 478
- miR-326
- miR-328
- cuggcccucucugcccuuccgu 479
- miR-328
- miR-330
- gcaaagcacacggccugcagaga 480
- miR-330
- miR-331
- gccccugggccuauccuagaa 481
- miR-331
- miR-335
- ucaagagcaauaacgaaaaaugu 482
- miR-335
- miR-337
- uccagcuccuauaugaugccuuu 483
- miR-337
- miR-338
- uccagcaucagugauuuuguuga 484
- miR-338
- miR-339
- ucccuguccuccaggagcuca 485
- miR-339
- miR-340
- uccgucucaguuacuuuauagcc 486
- miR-340
Claims (1)
-
imagen1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75640006P | 2006-01-05 | 2006-01-05 | |
US756400P | 2006-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2553442T3 true ES2553442T3 (es) | 2015-12-09 |
Family
ID=38256884
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07717734T Active ES2429404T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón |
ES12165734.0T Active ES2554531T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
ES12165740.7T Active ES2553442T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
ES12165748.0T Active ES2536438T3 (es) | 2006-01-05 | 2007-01-03 | Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07717734T Active ES2429404T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón |
ES12165734.0T Active ES2554531T3 (es) | 2006-01-05 | 2007-01-03 | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12165748.0T Active ES2536438T3 (es) | 2006-01-05 | 2007-01-03 | Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
Country Status (8)
Country | Link |
---|---|
US (3) | US7943318B2 (es) |
EP (4) | EP2514433B1 (es) |
JP (1) | JP5451077B2 (es) |
CN (3) | CN102943108B (es) |
AU (1) | AU2007205234B2 (es) |
CA (1) | CA2633674A1 (es) |
ES (4) | ES2429404T3 (es) |
WO (1) | WO2007081720A2 (es) |
Families Citing this family (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005078139A2 (en) * | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
DK2302055T3 (da) * | 2004-11-12 | 2014-10-13 | Asuragen Inc | Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler |
CN103882124B (zh) | 2005-08-01 | 2015-11-18 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
AU2006291165B2 (en) | 2005-09-12 | 2013-03-14 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
WO2007081720A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
CA2633754C (en) | 2006-01-05 | 2013-06-18 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
EP2591794A1 (en) | 2006-01-05 | 2013-05-15 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
EP2371971B1 (en) * | 2006-03-20 | 2013-11-27 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
US8207325B2 (en) * | 2006-04-03 | 2012-06-26 | Univ. of Copenhagen | MicroRNA biomarkers for human breast and lung cancer |
EP2455493B1 (en) | 2006-07-13 | 2014-01-08 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
EP2061907B1 (en) | 2006-09-19 | 2011-11-23 | The Ohio State University Research Foundation | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
EP2115138A2 (en) * | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008054828A2 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
CN103555825B (zh) | 2007-01-31 | 2015-09-30 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
US20100144850A1 (en) * | 2007-04-30 | 2010-06-10 | The Ohio State University Research Foundation | Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis |
US8465917B2 (en) | 2007-06-08 | 2013-06-18 | The Ohio State University Research Foundation | Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells |
CN101918424A (zh) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白 |
US8367632B2 (en) | 2007-07-31 | 2013-02-05 | Ohio State University Research Foundation | Methods for reverting methylation by targeting methyltransferases |
WO2009018493A1 (en) | 2007-07-31 | 2009-02-05 | The Board Of Regents Of The University Of Texas System | A micro-rna family that modulates fibrosis and uses thereof |
EP2173908B1 (en) | 2007-08-03 | 2016-01-06 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncrnas |
WO2009025790A1 (en) * | 2007-08-17 | 2009-02-26 | Catalyst Assets Llc | Diagnostic and prognostic use of human bladder cancer-associated micro rnas |
WO2009026487A1 (en) | 2007-08-22 | 2009-02-26 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
WO2009024790A1 (en) * | 2007-08-23 | 2009-02-26 | Isis Innovation Limited | Method and kit for the prognosis of cancer by determining the level of mirna-210 |
WO2009036332A1 (en) | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
WO2009044899A1 (ja) * | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | 細胞の増殖を制御する核酸 |
CA2702241A1 (en) * | 2007-10-11 | 2009-04-16 | The Ohio State University Research Foundation | Methods and compositions for the diagnosis and treatment of esophageal adenocarcinomas |
WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
CN103898069A (zh) | 2007-10-26 | 2014-07-02 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
US7927805B2 (en) * | 2007-10-30 | 2011-04-19 | Veridex, Llc | Process for predicting the prognosis of squamous cell lung cancer |
JP2011505143A (ja) * | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロrna発現プロファイリング及び肺癌における末梢血ターゲティング |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
JP5116026B2 (ja) | 2008-01-23 | 2013-01-09 | 富士フイルム株式会社 | 癌の検出方法および癌抑制剤 |
WO2009097136A1 (en) * | 2008-02-01 | 2009-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions relating to carcinoma stem cells |
CA2716906A1 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer |
WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
EP2806054A1 (en) | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
US20110071215A1 (en) * | 2008-06-02 | 2011-03-24 | Harvey Pass | Compositions and methods for diagnosis, prognosis and treatment of mesothelioma |
US8927207B2 (en) * | 2008-06-05 | 2015-01-06 | Research Foundation Of State University Of New York | miRNAs as therapeutic targets in cancer |
CN102149827B (zh) | 2008-06-11 | 2014-08-20 | 由卫生与公众服务部代表的***合众国政府 | MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途 |
WO2009153775A2 (en) * | 2008-06-17 | 2009-12-23 | Rosetta Genomics Ltd. | Methods for distinguishing between specific types of lung cancers |
EP2145964A1 (en) * | 2008-07-17 | 2010-01-20 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
CN102308004A (zh) * | 2008-10-30 | 2012-01-04 | 卡里斯生命科学卢森堡控股有限责任公司 | 评价rna图案的方法 |
WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
CN101475984A (zh) * | 2008-12-15 | 2009-07-08 | 江苏命码生物科技有限公司 | 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒 |
US20100240049A1 (en) | 2009-01-16 | 2010-09-23 | Cepheid | Methods of Detecting Cervical Cancer |
EP2379720B1 (en) | 2009-01-20 | 2016-08-17 | Alona Zilberberg | Mir-21 promoter driven targeted cancer therapy |
US20120058901A1 (en) * | 2009-02-13 | 2012-03-08 | The Board Of Regents Of The University Of Texas System | Assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1 |
CN102272330B (zh) * | 2009-02-23 | 2014-04-23 | 博奥生物有限公司 | 用于肺癌诊断、预后和提高生存率的试剂盒 |
US20100233704A1 (en) * | 2009-02-25 | 2010-09-16 | Cepheid | Methods of detecting lung cancer |
CN102549166A (zh) * | 2009-02-26 | 2012-07-04 | 俄亥俄州立大学研究基金会 | 从未吸烟者中的MicroRNA及相关材料和方法 |
IT1398768B1 (it) * | 2009-03-24 | 2013-03-18 | Zollo | Uso di microrna-199b-5p in campo medico e diagnostico. |
EP2414549A4 (en) | 2009-03-31 | 2013-08-28 | Us Health | DIFFERENTIAL EXPRESSION MICRO-RNA AS BIOMARKERS IN THE DIAGNOSIS OF SJÖGREN SYNDROME AND TREATMENT THEREOF |
US20110105585A1 (en) * | 2009-04-23 | 2011-05-05 | Northwestern University | METHODS FOR DIAGNOSING AND TREATING SQUAMOUS CELL CARCINOMA UTILIZING miRNA-205 AND INHIBITORS THEREOF |
EP2336353A1 (en) * | 2009-12-17 | 2011-06-22 | febit holding GmbH | miRNA fingerprints in the diagnosis of diseases |
JP5546064B2 (ja) * | 2009-07-09 | 2014-07-09 | 中国医学科学院▲腫▼瘤研究所 | 肺がん予後および薬物調製における2つのマイクロRNAsの使用 |
PL212748B1 (pl) * | 2009-07-30 | 2012-11-30 | Gdanski Univ Medyczny | Sposób okreslania ryzyka odleglego nawrotu niedrobnokomórkowego raka pluca u chorych w stopniu I-III A zaawansowania leczonych chirurgicznie |
EP2460005A4 (en) * | 2009-07-31 | 2012-11-21 | Translational Genomics Res Inst | METHOD FOR ASSESSING A CANCER PROGRESSION RISK |
EP2470897A4 (en) * | 2009-08-28 | 2013-05-29 | Asuragen Inc | MICRO-RNA BIOMARKERS OF PULMONARY DISEASE |
CN102018963B (zh) * | 2009-09-11 | 2013-03-13 | 中国科学院上海生命科学研究院 | 调节RANTES表达的miR-125a、其组合物及其用途 |
EP2486929B1 (en) * | 2009-10-01 | 2017-03-15 | National Cancer Center | Therapeutic agent for tumor |
CN102858997B (zh) * | 2009-11-02 | 2014-06-18 | 新加坡科技研究局 | 用于监测细胞状态和用于永生间充质干细胞的方法 |
US8916533B2 (en) | 2009-11-23 | 2014-12-23 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
CN102080083B (zh) * | 2009-12-01 | 2013-02-27 | 中国科学院上海药物研究所 | 人miR-149反义核酸及其应用 |
WO2011084815A1 (en) * | 2009-12-21 | 2011-07-14 | Board Of Trustees Of Southern Illinois University | Inhibition of ubc9-mediated cancer cell invasion and metastasis |
CN102782155B (zh) * | 2009-12-24 | 2016-05-04 | 复旦大学 | 用于肺癌的血浆中微rna表达谱分析的组合物和方法 |
CN102770561B (zh) * | 2009-12-24 | 2015-05-06 | 复旦大学 | 用于诊断不同亚型肺癌的基于组织的微-rna方法 |
WO2011076145A1 (en) * | 2009-12-24 | 2011-06-30 | Fudan University | Tissue-based micro-rna methods for diagnosis of different subtypes of lung cancer |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
US20120329060A1 (en) * | 2010-03-18 | 2012-12-27 | Jayaprakash Karkera | Diagnostic for lung cancer using mirna |
CA2794142A1 (en) * | 2010-03-26 | 2011-09-29 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by mir-155 |
WO2011125245A1 (ja) * | 2010-04-05 | 2011-10-13 | 財団法人癌研究会 | miRNAを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法 |
BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
WO2011150855A1 (en) * | 2010-06-04 | 2011-12-08 | Fudan University | Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma |
WO2011156777A1 (en) | 2010-06-10 | 2011-12-15 | Fred Hutchinson Cancer Research Center | Use of blood mir-210 for cancer prognosis |
CA2804599C (en) | 2010-07-06 | 2023-01-31 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
WO2012005339A1 (ja) | 2010-07-08 | 2012-01-12 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
WO2012065049A1 (en) | 2010-11-12 | 2012-05-18 | The Ohio State University Research Foundation | Materials and methods related to microrna-21, mismatch repair, and colorectal cancer |
CN103313706A (zh) | 2010-11-15 | 2013-09-18 | 俄亥俄州立大学研究基金会 | 控制释放粘膜粘合*** |
CN102140466B (zh) * | 2010-12-30 | 2013-03-27 | 苏州吉玛基因股份有限公司 | 人miR-1825反义核酸及其应用 |
CN102140467B (zh) * | 2010-12-30 | 2013-05-15 | 苏州吉玛基因股份有限公司 | 人miR-365反义核酸及其应用 |
EP2505663A1 (en) | 2011-03-30 | 2012-10-03 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | A method to identify asymptomatic high-risk individuals with early stage lung cancer by means of detecting miRNAs in biologic fluids |
WO2012097047A1 (en) * | 2011-01-11 | 2012-07-19 | The Ohio State University Research Foundation | Methods to identify chronic lymphocytic leukemia disease progression |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
CN102586412B (zh) * | 2011-01-18 | 2015-05-20 | 上海市第一人民医院 | 一种MicroRNA特异表达谱及其应用 |
WO2012103355A2 (en) | 2011-01-26 | 2012-08-02 | Cepheid | Methods of detecting lung cancer |
EP2670849A1 (en) | 2011-02-03 | 2013-12-11 | Mirna Therapeutics, Inc. | Synthetic mimics of mir-124 |
IT1403685B1 (it) * | 2011-02-07 | 2013-10-31 | Fond Irccs Istituto Naz Dei Tumori | Procedimento ed apparecchiatura per identificare individui a rischio di tumore polmonare e/o per diagnosticare un tumore polmonare, nonche' composizione e metodo per ridurre o eliminare il rischio di tumore polmonare. |
IT1406866B1 (it) * | 2011-02-07 | 2014-03-14 | Fond Irccs Istituto Naz Dei Tumori | Procedimento ed apparecchiatura per identificare individui a rischio di tumore polmonare e/o per diagnosticare un tumore polmonare, nonché composizione e metodo per ridurre o eliminare il rischio di tumore polmonare |
WO2012107841A2 (en) * | 2011-02-07 | 2012-08-16 | Biomirna Holdings Ltd. | Micro-rna biomarkers and methods of using same |
EP2683387A4 (en) | 2011-03-07 | 2014-09-03 | Univ Ohio State | MUTATORY ACTIVITY INDUCED BY INFLAMMATION OF MICROARN-155 (MIR-155) BINDING AND CANCER |
WO2012131670A2 (en) * | 2011-03-28 | 2012-10-04 | Rosetta Genomics Ltd | Methods for lung cancer clasification |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHODS AND MATERIALS RELATED TO OVARIAN CANCER |
EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
US9481885B2 (en) | 2011-12-13 | 2016-11-01 | Ohio State Innovation Foundation | Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis |
CN102533983A (zh) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | 癌症病理演变前期microrna-330水平原位杂交检测试剂盒及检测方法和应用 |
CN102533984A (zh) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | 癌症病理演变前期microrna17-3p水平原位杂交检测试剂盒及检测方法和应用 |
ITRM20110685A1 (it) * | 2011-12-23 | 2013-06-24 | Internat Ct For Genetic En Gineering And | Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci |
CN102559884A (zh) * | 2011-12-27 | 2012-07-11 | 芮屈生物技术(上海)有限公司 | 各种癌症病理演变前期let-7mirna水平原位杂交检测试剂盒及检测方法和应用 |
EP2804960A4 (en) | 2012-01-20 | 2015-08-19 | Univ Ohio State | BREAST CANCER BIOMARK SIGNATURES FOR INVASIVITY AND FORECAST |
CN102776194A (zh) * | 2012-07-20 | 2012-11-14 | 苏州大学 | 微小rna用于调控pten基因表达 |
US10196662B2 (en) * | 2012-08-10 | 2019-02-05 | Mello Biotechnology, Inc. | Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors |
EP3435084B1 (en) | 2012-08-16 | 2023-02-22 | Decipher Biosciences, Inc. | Prostate cancer prognostics using biomarkers |
KR101501826B1 (ko) * | 2013-04-05 | 2015-03-13 | 연세대학교 산학협력단 | 위암에 대한 예후 예측 모형의 제조방법 |
CN103285406B (zh) * | 2013-05-27 | 2015-05-13 | 哈尔滨医科大学 | microRNA-203及其拟似物在制备防治肥胖、血脂异常及其并发症药物中的应用 |
CN103751801A (zh) * | 2013-09-10 | 2014-04-30 | 上海大学 | 非小细胞肺癌中miR-143基因的应用 |
PL405648A1 (pl) | 2013-10-15 | 2015-04-27 | Warszawski Uniwersytet Medyczny | Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny |
PL406033A1 (pl) | 2013-11-14 | 2015-05-25 | Warszawski Uniwersytet Medyczny | Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny |
CN103948926A (zh) * | 2014-03-24 | 2014-07-30 | 江苏大学 | miR-9抑制剂在制备用于抑制肿瘤生长药物中的用途 |
CN104031987B (zh) * | 2014-05-12 | 2016-08-31 | 贵州省人民医院 | miRNA在心肌纤维化疾病治疗中的应用 |
CN104152452B (zh) * | 2014-08-19 | 2016-08-24 | 中国人民解放军总医院第一附属医院 | 一种与肝癌相关的血液miRNA标志物及其应用 |
US20160070852A1 (en) * | 2014-09-04 | 2016-03-10 | National Taiwan University | Prognosis prediction for acute myeloid leukemia by a 3-microrna scoring method |
CN104911248A (zh) * | 2014-12-18 | 2015-09-16 | 南京大学 | 一种用于ii、iii期结直肠癌诊断及预后的微小核糖核酸组合及其应用 |
CN104726448B (zh) * | 2014-12-29 | 2018-03-30 | 常州杰傲病理诊断技术有限公司 | 一种用于肺癌组织分型的miRNA标志物及应用 |
CN107709636A (zh) * | 2015-05-19 | 2018-02-16 | 威斯塔解剖学和生物学研究所 | 用于诊断或检测肺癌的方法和组合物 |
CN108138180A (zh) | 2015-06-05 | 2018-06-08 | 米拉根医疗股份有限公司 | 用于治疗皮肤t细胞淋巴瘤(ctcl)的mir-155抑制剂 |
CN105457041B (zh) * | 2015-12-09 | 2020-09-08 | 上海大学 | miR-26a在非小细胞肺癌中的应用 |
CN105561339B (zh) * | 2015-12-21 | 2019-02-22 | 江苏省人民医院 | 一种miRNA的组合制备抗非小细胞肺癌药物中的应用 |
CN105726559B (zh) * | 2016-03-21 | 2018-12-18 | 南通大学 | miRNA-17-3p和miRNA-19b-1组合物及其应用 |
ES2646826B1 (es) * | 2016-05-13 | 2018-10-01 | Servicio Andaluz De Salud | MicroARNs como biomarcadores para el diagnóstico del cáncer de pulmón |
US20200318110A1 (en) * | 2016-05-27 | 2020-10-08 | Lin Shi Lung | A composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancer |
CN106055921A (zh) * | 2016-05-27 | 2016-10-26 | 华中农业大学 | 基于基因表达和药物靶标的药物活性预测与筛选方法 |
US11053496B2 (en) | 2016-06-14 | 2021-07-06 | Agency For Science, Technology And Research | Consequences of a defective switch in cutaneous squamous cell carcinoma |
CN105950753B (zh) * | 2016-06-16 | 2019-10-01 | 朱伟 | 一种与肺腺癌辅助诊断相关的血浆miRNA标志物及其应用 |
KR101888744B1 (ko) | 2016-08-02 | 2018-10-04 | 연세대학교 산학협력단 | Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법 |
CN110506127B (zh) | 2016-08-24 | 2024-01-12 | 维拉科特Sd公司 | 基因组标签预测***癌患者对术后放射疗法应答性的用途 |
US10738363B2 (en) | 2016-08-31 | 2020-08-11 | National Central University | Analyzer and analytical method for predicting prognosis of cancer radiotherapy |
WO2018085198A1 (en) | 2016-11-01 | 2018-05-11 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
EP3545091A1 (en) * | 2016-11-25 | 2019-10-02 | Centre National De La Recherche Scientifique | Agents for the treatment of patients with nsclc and methods to predict response |
CN107058480B (zh) * | 2016-12-14 | 2018-07-13 | 河北医科大学第四医院(河北省肿瘤医院) | 用于诊断肺腺癌的长链非编码rna标志物 |
AU2018210695A1 (en) | 2017-01-20 | 2019-08-08 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
EP3571212B1 (en) * | 2017-01-23 | 2024-03-06 | Trustees of Boston University | Methods relating to lung cancer |
CN106755521B (zh) * | 2017-02-20 | 2019-03-08 | 南京盖斯夫医药科技有限公司 | 血浆microRNAs用于制备筛查诊断女性群体中肺腺癌患者的诊断试剂的用途 |
WO2018165600A1 (en) | 2017-03-09 | 2018-09-13 | Genomedx Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
US11078542B2 (en) | 2017-05-12 | 2021-08-03 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
CN113930503B (zh) * | 2017-08-14 | 2024-01-23 | 江苏为真生物医药技术股份有限公司 | miR-126和miR-152联合在制备诊断和预示肺癌的试剂或试剂盒中的应用 |
CN107475388B (zh) * | 2017-08-22 | 2020-05-19 | 深圳市恩普电子技术有限公司 | 鼻咽癌相关的miRNA作为生物标志物的应用及鼻咽癌检测试剂盒 |
CN108096266A (zh) * | 2017-11-30 | 2018-06-01 | 佛山英特医药科技有限公司 | miRNA-370在抗肿瘤作用、实施方法及用途 |
CN108841962B (zh) * | 2018-08-01 | 2021-11-19 | 博奥生物集团有限公司 | 一种非小细胞肺癌检测试剂盒及其应用 |
CN109207599A (zh) * | 2018-11-12 | 2019-01-15 | 觅瑞(杭州)生物科技有限公司 | 一种用于非小细胞肺癌诊断的外周血miRNA标志物 |
JP2020092688A (ja) * | 2018-12-12 | 2020-06-18 | 国立大学法人東海国立大学機構 | マイクロrnaを含む体液抽出物 |
CN109385478B (zh) * | 2018-12-20 | 2021-08-03 | 首都医科大学附属北京朝阳医院 | 检测19-gcs的基因标记在制备用于诊断早期肺腺癌预后的产品中的应用 |
CN111218513B (zh) * | 2020-04-24 | 2020-08-14 | 上海思路迪医学检验所有限公司 | 一种用于肺癌早期诊断的外周血胞外囊泡microRNA生物标志物及其用途 |
WO2023074135A1 (ja) * | 2021-11-01 | 2023-05-04 | 国立研究開発法人国立がん研究センター | 肺がんの予後の判定を補助する方法及び試薬キット |
CN116585342A (zh) * | 2023-05-23 | 2023-08-15 | 源生生物科技(青岛)有限责任公司 | 包含miRNA的活性成分及其应用 |
CN117286252B (zh) * | 2023-11-16 | 2024-04-09 | 上海交通大学医学院 | 一种诊断和预后评估肺癌的生物标志物组合及其应用 |
Family Cites Families (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
US4608337A (en) | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4701409A (en) | 1984-11-15 | 1987-10-20 | The Wistar Institute | Detection of B-cell neoplasms |
US4693975A (en) | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4712124A (en) * | 1986-12-22 | 1987-12-08 | North American Philips Corporation | Complementary lateral insulated gate rectifiers with matched "on" resistances |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
EP0341904B1 (en) | 1988-05-09 | 1995-03-29 | Temple University of the Commonwealth System of Higher Education | Method for predicting the effectiveness of antineoplastic therapy in individual patients |
US5198338A (en) | 1989-05-31 | 1993-03-30 | Temple University | Molecular probing for human t-cell leukemia and lymphoma |
US5149628A (en) | 1989-11-15 | 1992-09-22 | Temple University | Methods for detecting bcl-3 gene in human leukemias |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US6040140A (en) | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
US5633135A (en) | 1991-12-11 | 1997-05-27 | Thomas Jefferson University | Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities |
WO1993012136A1 (en) | 1991-12-11 | 1993-06-24 | Thomas Jefferson University | Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
CA2148350A1 (en) | 1992-10-29 | 1994-05-11 | Carlo Croce | Methods of detecting micrometastasis of prostate cancer |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US7175995B1 (en) | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
US5985598A (en) | 1994-10-27 | 1999-11-16 | Thomas Jefferson University | TCL-1 gene and protein and related methods and compositions |
US5695944A (en) | 1995-05-05 | 1997-12-09 | Thomas Jefferson University | Modulation of bcl-2 phosphorylation |
US5567586A (en) | 1995-05-18 | 1996-10-22 | Thomas Jefferson University | Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region |
US6242212B1 (en) | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
US5928884A (en) | 1996-02-09 | 1999-07-27 | Croce; Carlo M. | FHIT proteins and nucleic acids and methods based thereon |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US6187536B1 (en) | 1997-02-18 | 2001-02-13 | Thomas Jefferson University | Methods of identifying and detecting pancreatic cancer |
EP0972083A1 (en) | 1997-04-04 | 2000-01-19 | THE TEXAS A&M UNIVERSITY SYSTEM | Noninvasive detection of colonic biomarkers using fecal messenger rna |
CA2335315A1 (en) | 1998-07-20 | 2000-01-27 | Thomas Jefferson University | Nitrilase homologs |
AU5128999A (en) | 1998-07-24 | 2000-02-14 | Yeda Research And Development Co. Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
EP1165586A4 (en) | 1999-03-15 | 2003-05-28 | Univ Jefferson | TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS |
US7163801B2 (en) | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
SE0000522D0 (sv) * | 2000-02-17 | 2000-02-17 | Astrazeneca Ab | Mixing apparatus |
US6891031B2 (en) | 2000-02-18 | 2005-05-10 | The Regents Of The University Of California | Coordinate cytokine regulatory sequences |
US20010026796A1 (en) | 2000-03-14 | 2001-10-04 | Croce Carlo M. | TCL1 enhances Akt kinase activity and mediates its nuclear translocation |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
US6924414B2 (en) | 2000-04-11 | 2005-08-02 | Thomas Jefferson University | Muir-torre-like syndrome in Fhit deficient mice |
WO2001087958A2 (en) | 2000-05-16 | 2001-11-22 | Thomas Jefferson University | CRYSTAL STRUCTURE OF WORM NitFhit REVEALS THAT A Nit TETRAMER BINDS TWO Fhit DIMERS |
US7060811B2 (en) | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
US20040033502A1 (en) | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
EP2428571B1 (en) | 2001-09-28 | 2018-07-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
GB0128898D0 (en) | 2001-12-03 | 2002-01-23 | Biotech Res Ventures Pte Ltd | Materials and methods relating to the stabilization and activation of a tumour suppressor protein |
KR101210018B1 (ko) | 2002-03-08 | 2012-12-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 약물로서 유용한 거대고리 화합물 |
AU2003226279A1 (en) | 2002-04-08 | 2003-10-27 | Ciphergen Biosystems, Inc. | Serum biomarkers in hepatocellular carcinoma |
CA2484920A1 (en) | 2002-04-29 | 2003-11-13 | Thomas Jefferson University | Human chronic lymphocytic leukemia modeled in mouse by targeted tcl1 expression |
AU2003273542A1 (en) | 2002-05-31 | 2003-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying and isolating stem cells and cancer stem cells |
AU2003253618B2 (en) | 2002-05-31 | 2007-11-15 | The Regents Of The University Of California | Method for efficient RNA interference in mammalian cells |
US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
JP2006512908A (ja) | 2002-10-11 | 2006-04-20 | トーマス ジェファーソン ユニバーシティー | 腫瘍抑制遺伝子および組成物ならびにその作製法および使用法 |
US20050266443A1 (en) | 2002-10-11 | 2005-12-01 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
CN102304570B (zh) | 2002-11-13 | 2015-01-21 | 托马斯杰斐逊大学 | 用于癌症诊断和治疗的组合物和方法 |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2004071464A2 (en) | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
US7183384B2 (en) | 2003-03-06 | 2007-02-27 | A & G Pharmaceutical, Inc. | Monoclonal antibody 7H11 reactive with human cancer |
AU2003286741A1 (en) | 2003-05-02 | 2004-11-26 | Thomas Jefferson University | Methods and compositions for diagnosis and therapy of parkin-associated disorders |
WO2006031210A1 (en) | 2003-05-29 | 2006-03-23 | Board Of Regents, The University Of Texas Systems | Jabi as a prognostic marker and a therapeutic target for human cancer |
EP1644492B1 (en) | 2003-06-18 | 2009-01-07 | Genelux Corporation | Modified recombinant vaccinia viruses, uses thereof |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
US20050037362A1 (en) | 2003-08-11 | 2005-02-17 | Eppendorf Array Technologies, S.A. | Detection and quantification of siRNA on microarrays |
US8412541B2 (en) | 2003-08-14 | 2013-04-02 | Edda Technology, Inc. | Method and system for intelligent qualitative and quantitative analysis for medical diagnosis |
US20050084883A1 (en) | 2003-08-25 | 2005-04-21 | The Johns Hopkins University School Of Medicine | Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis |
EP1670955A2 (en) | 2003-09-22 | 2006-06-21 | Rosetta Inpharmatics LLC. | Synthetic lethal screen using rna interference |
EP1668155A2 (en) | 2003-09-24 | 2006-06-14 | Oncotherapy Science, Inc. | Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc) |
US20050186589A1 (en) | 2003-11-07 | 2005-08-25 | University Of Massachusetts | Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi |
US20050164252A1 (en) | 2003-12-04 | 2005-07-28 | Yeung Wah Hin A. | Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell |
DE602004031881D1 (de) | 2003-12-19 | 2011-04-28 | Univ California | Verfahren und materialien zur beurteilung von prostatakrebstherapien |
WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
US20050256072A1 (en) * | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
CA2556435C (en) | 2004-02-13 | 2014-08-12 | The Rockefeller University | Anti-microrna oligonucleotide molecules |
AU2005214286A1 (en) | 2004-02-23 | 2005-09-01 | Erasmus University Medical Center Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
KR20070004957A (ko) | 2004-04-20 | 2007-01-09 | 제나코 바이오메디컬 프로덕츠, 인코포레이티드 | ncRNA 검출 방법 |
EP1784501B1 (en) | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
US20060037088A1 (en) | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
EP2338994B1 (en) | 2004-09-02 | 2014-03-19 | Yale University | Regulation of oncogenes by microRNAs |
US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
US7592441B2 (en) | 2004-10-04 | 2009-09-22 | Rosetta Genomics Ltd | Liver cancer-related nucleic acids |
FR2877350B1 (fr) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
DK2302055T3 (da) | 2004-11-12 | 2014-10-13 | Asuragen Inc | Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler |
WO2006066158A2 (en) | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
EP1959012A3 (en) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
WO2006081284A2 (en) | 2005-01-25 | 2006-08-03 | Rosetta Inpharmatics Llc | Methods for quantitating small rna molecules |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
GB2425311A (en) | 2005-04-15 | 2006-10-25 | Ist Superiore Sanita | Micro RNA against kit protein |
US8247543B2 (en) | 2005-04-29 | 2012-08-21 | The Rockefeller University | Human microRNAs and methods for inhibiting same |
WO2006133022A2 (en) | 2005-06-03 | 2006-12-14 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
US20070065844A1 (en) | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
US20060292616A1 (en) | 2005-06-23 | 2006-12-28 | U.S. Genomics, Inc. | Single molecule miRNA-based disease diagnostic methods |
CN103882124B (zh) | 2005-08-01 | 2015-11-18 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
CA2618995A1 (en) | 2005-08-10 | 2007-02-22 | The Rockefeller University | Antagomirs for use in inhibiting mir-122 |
AU2006291165B2 (en) | 2005-09-12 | 2013-03-14 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
WO2007044413A2 (en) | 2005-10-05 | 2007-04-19 | The Ohio State University Research Foundation | Wwox gene, vectors containing the same, and uses in treatment of cancer |
US7390792B2 (en) | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
EP2591794A1 (en) | 2006-01-05 | 2013-05-15 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
WO2007081720A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
CA2633754C (en) | 2006-01-05 | 2013-06-18 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
US20090007281A1 (en) | 2006-01-13 | 2009-01-01 | Battelle Memorial Institute | Animal Model for Assessing Copd-Related Diseases |
EP2371971B1 (en) | 2006-03-20 | 2013-11-27 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
WO2007112097A2 (en) | 2006-03-24 | 2007-10-04 | Children's Medical Center Corporation | Novel signature self renewal gene expression programs |
DK2666859T3 (en) | 2006-04-03 | 2019-04-08 | Roche Innovation Ct Copenhagen As | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES |
WO2007127190A2 (en) | 2006-04-24 | 2007-11-08 | The Ohio State University Research Foundation | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
EP2455493B1 (en) | 2006-07-13 | 2014-01-08 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
US20080193943A1 (en) | 2006-09-05 | 2008-08-14 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
CA2663878A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
EP2061907B1 (en) | 2006-09-19 | 2011-11-23 | The Ohio State University Research Foundation | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
EP2115138A2 (en) | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
WO2008054828A2 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
US8293684B2 (en) | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
WO2008070082A2 (en) | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
CN101622348A (zh) | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为治疗性干预靶标的miR-20调节的基因和途径 |
CA2671299A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
EP2104734A2 (en) | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
CA2671294A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
CA2671270A1 (en) | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
CN103555825B (zh) | 2007-01-31 | 2015-09-30 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
WO2008124777A1 (en) | 2007-04-10 | 2008-10-16 | National Taiwan University | Predicting post-treatment survival in cancer patients with micrornas |
US20100144850A1 (en) | 2007-04-30 | 2010-06-10 | The Ohio State University Research Foundation | Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis |
US20090005336A1 (en) | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
US20090232893A1 (en) | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090131354A1 (en) | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
US8465917B2 (en) | 2007-06-08 | 2013-06-18 | The Ohio State University Research Foundation | Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells |
AU2008261951A1 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | miR-34 regulated genes and pathways as targets for therapeutic intervention |
CN101918424A (zh) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白 |
US8367632B2 (en) | 2007-07-31 | 2013-02-05 | Ohio State University Research Foundation | Methods for reverting methylation by targeting methyltransferases |
EP2173908B1 (en) | 2007-08-03 | 2016-01-06 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncrnas |
WO2009026487A1 (en) | 2007-08-22 | 2009-02-26 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
US20090061424A1 (en) | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
EP2775001B1 (en) | 2007-09-06 | 2016-03-09 | The Ohio State University Research Foundation | MicroRNA signatures in human ovarian cancer |
CA2702241A1 (en) | 2007-10-11 | 2009-04-16 | The Ohio State University Research Foundation | Methods and compositions for the diagnosis and treatment of esophageal adenocarcinomas |
CN103898069A (zh) | 2007-10-26 | 2014-07-02 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
AU2008321253B2 (en) | 2007-11-12 | 2014-01-16 | Masaryk Memorial Cancer Institute | Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
US20090123933A1 (en) | 2007-11-12 | 2009-05-14 | Wake Forest University Health Sciences | Microrna biomarkers in lupus |
JP2011505143A (ja) | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロrna発現プロファイリング及び肺癌における末梢血ターゲティング |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
WO2009086156A2 (en) | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
ES2936256T3 (es) | 2008-02-01 | 2023-03-15 | Massachusetts Gen Hospital | Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas |
WO2009100430A2 (en) | 2008-02-08 | 2009-08-13 | Asuragen, Inc | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
CN102007408A (zh) | 2008-02-28 | 2011-04-06 | 俄亥俄州立大学研究基金会 | 与急性髓性白血病(aml)中的细胞遗传学和预后相关的微rna特征及其用途 |
US20110052502A1 (en) | 2008-02-28 | 2011-03-03 | The Ohio State University Research Foundation | MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof |
CA2716906A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer |
EP3112477A1 (en) | 2008-02-28 | 2017-01-04 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders |
EP2268832A2 (en) | 2008-03-06 | 2011-01-05 | Asuragen, INC. | Microrna markers for recurrence of colorectal cancer |
WO2009154835A2 (en) | 2008-03-26 | 2009-12-23 | Asuragen, Inc. | Compositions and methods related to mir-16 and therapy of prostate cancer |
WO2009137807A2 (en) | 2008-05-08 | 2009-11-12 | Asuragen, Inc. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
CN102112110A (zh) | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | 用于RNAi试剂体内递送的新型组合物 |
CN102149827B (zh) | 2008-06-11 | 2014-08-20 | 由卫生与公众服务部代表的***合众国政府 | MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途 |
WO2010019694A1 (en) | 2008-08-12 | 2010-02-18 | The Ohio State University Research Foundation | Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma |
JP2012509886A (ja) | 2008-11-21 | 2012-04-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 転写制御因子としてのTcl1 |
WO2010065156A1 (en) | 2008-12-05 | 2010-06-10 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer |
CN102549166A (zh) | 2009-02-26 | 2012-07-04 | 俄亥俄州立大学研究基金会 | 从未吸烟者中的MicroRNA及相关材料和方法 |
-
2007
- 2007-01-03 WO PCT/US2007/000103 patent/WO2007081720A2/en active Application Filing
- 2007-01-03 EP EP12165734.0A patent/EP2514433B1/en not_active Not-in-force
- 2007-01-03 CN CN201210312507.1A patent/CN102943108B/zh not_active Expired - Fee Related
- 2007-01-03 CN CN2007800067508A patent/CN101400361B/zh not_active Expired - Fee Related
- 2007-01-03 JP JP2008549549A patent/JP5451077B2/ja not_active Expired - Fee Related
- 2007-01-03 EP EP12165740.7A patent/EP2514434B1/en not_active Not-in-force
- 2007-01-03 ES ES07717734T patent/ES2429404T3/es active Active
- 2007-01-03 EP EP07717734.3A patent/EP1978986B1/en not_active Not-in-force
- 2007-01-03 ES ES12165734.0T patent/ES2554531T3/es active Active
- 2007-01-03 ES ES12165740.7T patent/ES2553442T3/es active Active
- 2007-01-03 CA CA002633674A patent/CA2633674A1/en not_active Abandoned
- 2007-01-03 US US12/160,034 patent/US7943318B2/en active Active
- 2007-01-03 CN CN201410210166.6A patent/CN103993082B/zh not_active Expired - Fee Related
- 2007-01-03 EP EP12165748.0A patent/EP2502630B1/en not_active Not-in-force
- 2007-01-03 ES ES12165748.0T patent/ES2536438T3/es active Active
- 2007-01-03 AU AU2007205234A patent/AU2007205234B2/en not_active Ceased
-
2011
- 2011-03-30 US US13/075,820 patent/US8361710B2/en not_active Expired - Fee Related
- 2011-03-30 US US13/075,828 patent/US8377637B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2553442T3 (es) | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón | |
ES2545360T3 (es) | Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos | |
CN101384273B (zh) | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 | |
JP2008519606A5 (es) | ||
AU2014203454B2 (en) | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer | |
AU2013245505A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers | |
AU2013206405B2 (en) | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors | |
AU2016202133A1 (en) | MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |